As negotiations take place this week, an evaluation of the impact of one of the TRIPS-plus measures of the Mercosur/EU FTA on the prices of medicines in Brazil has been released. Based on the draft of the agreement, by their calculations, an additional USD 444 million would be necessary to be spent by the public health system for the purchase of six medicines alone, write Marcela Fogaça Vieira and Gabriela Costa Chaves.
Go to Source
Author: Guest contributor
facebooks